ORP-110
ORP-110 is a discovery-stage, metabolically-stable P2Y receptor ligand.
Overview
ORP-101
ORP-105
ORP-110
About
Overview
Leadership
Board of Directors
Scientific Advisors
Investors
Science
Pipeline
Overview
ORP-101
ORP-105
ORP-110
Licensing
Newsroom
News and Press Releases
OrphoMed, Inc. Announces Positive Phase 2 Results for ORP-101 100 mg Once-Daily Dose in IBS-D Patients
OrphoMed’s ORP-101 Passes Second Planned Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients
OrphoMed Passes First Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients
OrphoMed Resumes Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D
OrphoMed Pauses Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D
OrphoMed to Present Phase 1 Results of ORP-101 at Digestive Disease Week 2020
OrphoMed Initiates U.S. Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D
OrphoMed to Present at the 2019 BIO Investor Forum
OrphoMed Announces Formation of Scientific Advisory Board
FDA Grants Fast Track Designation for OrphoMed’s ORP-101 for Treatment of IBS-D
OrphoMed Appoints Gary M. Phillips, M.D. as President and Chief Executive Officer
OrphoMed featured in Wall Street Journal article on intestinal-focused startups
OrphoMed to Present at the 2018 BIO CEO & Investor Conference
OrphoMed Appoints Mark Sostek, M.D. as Chief Medical Officer
OrphoMed to Present at the 2017 BIO Investor Forum
OrphoMed Secures $39 Million Series A Financing Round
FierceBiotech: Takeda and NEA back $39M series A for GI biotech OrphoMed
OrphoMed Announces Late-breaking Plenary Session Presentation of New Preclinical Data for ORP-101 in IBS-D at Digestive Disease Week 2017
Events and Presentations
Contact